Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

Conforti, Rosa; Boulet, Thomas; Tomasic, Gorana; Taranchon, E.; Arriagada, R.; Spielmann, M.; Ducourtieux, M.; Soria, J-C.; Tursz, Thomas; Delaloge, Suzette; Michiels, Stefan; Varga, Andrea

doi:10.1093/annonc/mdm209

Cited by 77 publications

(58 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results from a few retrospective exploratory studies suggest that cancers of the basal cell or the HER2+/ER-subtype may respond more often to chemotherapy than cancers of the luminal type (32,33), although women with cancer of the HER2+/ER-or the basallike type tend to have an unfavorable outcome (29,30).…”

Section: Discussionmentioning

confidence: 99%

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Sihto

Lundin²,

Lehtimäki³

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The frequency and significance of gene expression profile-derived molecular subtypes of breast cancers found in mammography screening are unknown. Experimental Design: We identified breast cancers diagnosed in women of any age living in defined geographic regions in Finland in 1991 to 1992 and collected clinical and pathologic data. Surrogates for the molecular subtypes were determined for 247 cancers found in organized mammography screening and 989 cancers detected outside of screening using immunohistochemistry or in situ hybridization. Molecular subtypes were defined as luminal A [estrogen receptor (ER) positive and/or progesterone receptor (PR) positive, HER2-], luminal B (ER+ and/ or PR+, HER2+), basal-like (ER-, PR-, HER2-, cytokeratin 5+, and/or HER1+), HER2+/ER-(ER-, PR-, and HER2+), and unclassified. The median follow-up time was 9.4 years. Results: The luminal type A was common (73.7%) and the HER2+/ER-type is rare (5.7%) in screen-detected cancer, and only 16% were HER2 positive. Women with cancer diagnosed in screening at ages 50 to 69 years had similar molecular subtype distribution as women whose cancer was found outside of screening at age >69 years. In a multivariate model, cancer detection at screening independently predicted favorable distant disease-free survival when the molecular subtype was included as a covariate in addition to age, histologic grade, and cancer size. Women with small (pT 1 N 0 M 0 ) HER2-positive cancer had similar outcome regardless of the method of detection. Conclusions: Molecular subtype distribution of screen-detected breast cancer differs from that of cancers found outside of screening and accounts in part for the better outcome of screen-detected cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Sihto

Lundin²,

Lehtimäki³

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…However, as mentioned above, AIs are increasingly being used as standard treatment in postmenopausal women with breast cancer. Endocrine therapy is indicated for the treatment of hormone receptorpositive breast cancer, which generally has low sensitivity to chemotherapy [35,36]. Recently, AI-based endocrine therapy combined with chemotherapy was reported to be therapeutically useful.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Usefulness of Postoperative Adjuvant Chemotherapy with Tegafur–Uracil (UFT) in Patients with Breast Cancer: Focus on the Results of Clinical Studies in Japan

Nakayama

Noguchi

2010

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Primary tumors from 823 (88%) of the 935 patients included at IGR were used to build a tissue array [15]. The tissue array contained three spots of each primary tumor.…”

Section: Tissue Array and Immunostainingmentioning

confidence: 99%

“…A tumor was considered positive for CXCR4 staining if at least two spots were scored Ն1ϩ. In addition, immunostaining was performed for ER and HER-2 as previously described [15].…”

Section: Tissue Array and Immunostainingmentioning

confidence: 99%

CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence

et al. 2009

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Assess CXCR4 expression in the primary tumor for use as an indicator of a higher risk for bone metastasis in early breast cancer.2. Evaluate the relationship between CXCR4 expression and the occurrence of metastases in other SDF-1-producing organs, including the liver and lung.3. Use CXCR4 in different ways in combination with other markers to identify patients to be screened for bony metastases and/or treated preventatively for bone metastasis.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTBackground. Chemokine receptor 4 (CXCR4) has been demonstrated to have a critical role in the early metastatic process. The aim of this study was to eval-

show abstract

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

Abstract: The breast cancer molecular subclassification was predictive for chemotherapy efficacy in adjuvant setting, but did not provide significant additional information to ER.

Cited by 77 publications

References 26 publications

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Therapeutic Usefulness of Postoperative Adjuvant Chemotherapy with Tegafur–Uracil (UFT) in Patients with Breast Cancer: Focus on the Results of Clinical Studies in Japan

CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence

Contact Info

Product

Resources

About